

Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review

Maarten Naesens¹ Stefan Berger², Luigi Biancone³, Marta Crespo^{4,5}, Arjang Djamali⁶, Alexandre Hertig⁷, Robert Öllinger⁸, José Portolés⁹, Andreas Zuckermann¹⁰, Julio Pascual^{4,5}

1. KU Leuven - University of Leuven, Department of Microbiology and Immunology; University Hospitals Leuven, Department of Nephrology, B-3000 Leuven, Belgium
2. Department of Internal Medicine, University Medical Center, Groningen, Netherlands
3. Department of Nephrology, Dialysis and Transplantation, Ospedale Le Molinette Torino Corso, Torino, Italy
4. Department of Nephrology, Hospital del Mar, Barcelona, Spain
5. Institute Mar D'Investigacions Mediques, Barcelona, Spain
6. Department of Medicine, Division of Nephrology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WA, USA
7. Department of Emergency Nephrology and Renal Transplantation, Hôpital Tenon, Sorbonne Universités, Paris, France
8. Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
9. Department of Nephrology Hospital Puerta de Hierro, Madrid, Spain
10. Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

Contact for correspondence

Pr Julio Pascual

Department of Nephrology, Hospital del Mar

Passeig Maritim 25-29, 08003 Barcelona, Spain

Tel: +34 932483162 Email: julpascual@gmail.com

Running head: Induction and steroid minimization

Author email addresses:

Maarten Naesens	maarten.naesens@uzleuven.be maartennaesens@gmail.com
Stefan Berger	s.p.berger@umcg.nl
Luigi Biancone	luigi.biancone@unito.it
Marta Crespo	MCrespo@parcdesalutmar.cat
Arjang Djamali	axd@medicine.wisc.edu
Alexandre Hertig	alexandre.hertig@tnn.aphp.fr
Robert Öllinger	robert.oellinger@charite.de
José Portolés	josem.portoles@salud.madrid.org
Andreas Zuckermann	andreas.zuckermann@meduniwien.ac.at
Julio Pascual	julpascual@gmail.com jpascualsantos@parcdesalutmar.cat

Abstract

Steroid minimization after kidney transplantation has become more widely practiced as transplant clinicians seek the potential benefits such as reduced cardiovascular risk factors, improved growth in pediatric patients, and improved compliance with the immunosuppression regimen. Steroid avoidance (i.e. no steroids after the first week) is generally favored compared to later withdrawal. Induction therapy is routine in this setting, frequently rabbit antithymocyte globulin (rATG, Thymoglobulin[®]) or off-license use of alemtuzumab. Direct comparisons of steroid minimization regimens versus standard steroid regimens are rare. However, the available data show that the risk of acute rejection is low when rATG or alemtuzumab induction is given to support steroid-avoidance regimens after kidney transplantation. Steroid avoidance may be inadvisable in patients at high immunological risk or at risk of recurrent glomerular disease. Steroid withdrawal after day 8 may be possible without additional risk of rejection in patients given rATG induction, but while encouraging, the data are too sparse for firm conclusions. In summary, steroid avoidance may be beneficial for patients after renal transplantation, with the potential to avoid or reduce steroid-related comorbidities. Whilst depleting induction therapy could be the treatment of choice, results of prospective randomized, controlled studies are eagerly awaited.

Keywords: induction, depleting, steroid sparing, avoidance, kidney transplantation, ATG, rabbit antithymocyte globulin, Thymoglobulin, alemtuzumab, Campath

Inducción con anticuerpos antilinfocitarios y minimización de esteroides en trasplante renal

Abstract

La minimización de esteroides después del trasplante renal constituye una práctica muy extendida, en la búsqueda de potenciales beneficios cardiovasculares, mejor crecimiento en pacientes pediátricos o aumento de la adherencia al tratamiento inmunosupresor. El uso de inducción depletiva con ATG de conejo o alemtuzumab puede contribuir a evitar el uso de esteroides o al menos permitir su suspensión precoz. Esta estrategia se ha revisado en la literatura, añadiendo la opinión de expertos al análisis. La suspensión de esteroides muy precoz (antes de la primera semana) parece preferirse a la suspensión más tardía. En ese contexto, la inducción preventiva es la práctica más utilizada, habitualmente con globulina antitimocítica de conejo (rATG, Tymoglobulin) o alemtuzumab (en uso fuera de indicación). Son raras las comparaciones directas de los regímenes de minimización de esteroides con los de uso estándar. Sin embargo, los datos disponibles muestran que el riesgo de rechazo agudo es bajo cuando se administra rATG o alemtuzumab para facilitar la suspensión muy precoz de esteroides. Esta práctica puede ser menos aconsejable en pacientes con alto riesgo inmunológico o predispuestos a una recurrencia de la enfermedad glomerular de base. La suspensión de esteroides a partir del día 8 es factible sin que el riesgo de rechazo aumente en pacientes tratados con rATG. No obstante, y aunque los datos disponibles así lo sugieren, requieren confirmación definitiva. En conclusión, la minimización extrema de esteroides puede ser beneficiosa en pacientes que reciben un trasplante renal, con la ventaja que supone evitar o reducir la comorbilidad asociada con ese tratamiento. Si bien la inducción depletiva podría ser el tratamiento de elección en

ese contexto, son necesarios nuevos ensayos aleatorizados controlados que lo confirmen.

Palabras clave: inducción, depleción, ahorro de esteroides, suspensión de esteroides, trasplante renal, ATG, glomulina antitimocítica de conejo, Timoglobulina, alemtuzumab

1. Introduction

Steroid-sparing immunosuppressive regimens are widely used after kidney transplantation as clinicians seek to minimize steroid-related adverse events¹. Rapid steroid discontinuation lowers the rates of cataracts, vascular necrosis and cytomegalovirus infection² and may improve growth in children³. Cardiovascular benefits are less well established, although positive effects have been observed for lipid profile and weight gain^{4,5}. Generally, it is difficult to demonstrate differences in randomized trials in unselected populations, and studies of steroid minimization regimens have often not reported steroid-related side effects, or were underpowered to demonstrate a significant difference. However, even if data remain unconvincing about reduced cardiovascular risk, the non-cardiovascular side effects of chronic steroid therapy require costly management⁶ and some, such as weight gain, can adversely affect patient compliance^{7,8} with potential consequences for graft outcomes.

Strategies for steroid minimization comprise either '*steroid avoidance*' (or '*steroid-free*') regimens, which will be defined here as no intravenous (i.v.) or oral steroids after the first 1–2 weeks post-transplant, or *steroid withdrawal* i.e. steroid discontinuation after weeks 1–2^{4,9,10}.

Steroid avoidance protocols have become increasingly popular in recent years. Steroid-free immunosuppression without induction therapy has been attempted after kidney transplantation using a calcineurin inhibitor (CNI)-based maintenance regimen, but randomized trials showed acute rejection to be significantly more frequent^{4,11,12} or more severe¹³ than with standard steroids. A series of randomized trials comparing steroid avoidance versus ongoing steroid therapy in selected populations receiving interleukin-2 receptor (IL-2R) induction have reported mixed results^{14–18}. High rates of biopsy-proven

acute rejection (BPAR) were observed in the FREEDOM study for patients given basiliximab induction with cyclosporine (CsA), mycophenolic acid (MPA) and either a single i.v. dose of steroids (31.5% BPAR at 1 year) or steroids to day 7 (26.1%)¹⁹. Other researchers have found no significant effect on BPAR using steroid avoidance with IL-2R antagonist induction, especially with concomitant tacrolimus^{15,16}, although BPAR may occur earlier¹⁶.

Many centers, particularly in the US, instead employ lymphocyte-depleting induction when steroid-free therapy is planned, an approach that may be partly based on experience from conventional immunosuppressive regimens. Randomized trials of patients at low or moderate immunological risk given standard steroids have shown comparable rejection rates using induction with an IL-2R antagonist or rabbit antithymocyte globulin (rATG)^{19–22}, but for high-immunologic risk populations both the overall rejection rate and the incidence of steroid-resistant rejection is lower with rATG^{23,24}. This may have encouraged more frequent selection of rATG or another depleting agent when attempting steroid avoidance: almost 90% of kidney transplantation patients who are discharged on a steroid-free regimen in the US receive a lymphocyte-depleting induction agent²⁵, with the remaining 10% given IL-2R antagonist induction.

Steroid withdrawal after the first week post-transplant tends to be regarded with more caution. A meta-analysis of eight randomized trials found that steroid withdrawal after week 1 significantly increased both acute rejection and graft loss²⁶. In a further meta-analysis, in which only those trials that included CNI therapy with mycophenolate mofetil (MMF) were analyzed, graft loss was minimized, but the risk of acute rejection was still higher following steroid withdrawal²⁷. The Kidney Disease: Improving Global Outcomes (KDIGO) recommendations suggest that in low-risk patients given induction therapy,

steroids can be discontinued during week 1²⁸. If steroids are administered beyond the first week post-transplant, however, KDIGO suggests that they be maintained thereafter²⁸. This may, however, be an oversimplification. A recent Cochrane systematic review concluded that although late (month 3–6) steroid withdrawal is associated with increased rejection rates in CsA-treated patients (risk ratio 1.61, $p=0.0018$), this does not appear to be the case when tacrolimus is given with MMF (risk ratio 0.82, $p=0.29$)^{9,10,29,30}. Equally, the safety of steroid withdrawal may be affected by the choice of induction therapy.

This article reviews the evidence relating to lymphocyte-depleting induction with rATG or alemtuzumab to support steroid avoidance or withdrawal in kidney transplant recipients. It should be borne in mind that alemtuzumab in solid organ transplantation is used off-label, and the indication is not likely to be forthcoming.

2. Lymphocyte-depleting induction & steroid-free immunosuppression

2.1 rATG induction

Randomized trials relating to steroid-free treatment of kidney transplant patients given rATG induction are relatively rare, with only sparse data directly comparing steroid-free therapy versus standard steroids (Table 1). One may deduce, however, that steroid-free immunosuppression is safe, as shown in trials such as the one published in 2005 by Kandaswamy *et al*³¹. In that study, 239 first or second kidney transplant recipients all received rATG (1.25–1.5 mg/kg for five doses) with a single dose of i.v. steroids then oral steroids to day 5³¹. The trial did not compare steroid-free with steroid conventional therapy: instead, all patients received the very short five-day steroid regimen. They were randomized to one of three maintenance regimens: CsA with MMF, high tacrolimus

(trough level 8–12 ng/mL) with low sirolimus (3–7 ng/mL), or low tacrolimus (3–7 ng/mL) with high sirolimus (8–12 ng/mL), and followed to month 24. Rates of BPAR were low and similar in all groups (4–6%); graft and patient survival was also excellent (Table 1). At month 24, 75%, 90% and 83% of patients, respectively, remained steroid-free, and the incidence of steroid-related events (post-lymphoproliferative disease, new-onset diabetes mellitus [NODAT], osteonecrosis and viral infection) was encouragingly low. There were no major differences in complications between groups, other than a higher rate of wound healing complications in the high sirolimus arm ($p=0.02$)³¹. These results suggest that any of these steroid-free maintenance protocols is effective when given with rATG induction, even in an unselected cohort of patients.

One randomized trial that compared rATG induction with or without ongoing steroids was a 12-month single-center study in 60 first or second kidney transplant recipients³². In fact, what made this trial unique is that it compared steroid-free versus standard steroids as the single variation between the comparative arms. The rATG dose was 1 mg/kg, for three to five doses, with a seven-day course of i.v. steroids. Patients received tacrolimus with MMF, with or without oral steroids. Graft function and rates of clinical rejection (13% versus 11% in controls) were unaffected by the absence of steroid therapy. Protocol biopsies were undertaken in 19 patients at month 12, and although subclinical rejection rates were similar in both arms, the increase in fibrosis at 6 and especially at 12 months was significantly greater in the steroid-avoidance group ($p<0.001$), a potential cause for concern although in most patients fibrosis was mild (grade 1). Assessment of subclinical changes by protocol biopsies may be an important focus in future studies of steroid avoidance.

Woodle *et al* undertook a multicenter, randomized trial in which 151 living-donor kidney transplant patients were given either rATG (1.25–1.5 mg/kg for four days) with steroids

discontinued by day 6, or to no induction with standard i.v. and oral steroids until at least month 3 post-transplant⁵. All patients were given tacrolimus and MMF, and dosing was similar in both treatment groups. By month 12, 72% of rATG-treated patients remained steroid-free, while in the control arm only 12% of patients managed to stop steroids. The 12-month incidence of BPAR was 13.9% versus 19.4% for the rATG/steroid-free group versus the control arm (n.s.) (Figure 1). In terms of steroid-related adverse events, levels of total cholesterol was significantly lower in the steroid-free group at 12 months post-transplant, with a trend to less weight gain ($p=0.07$)⁵.

Other randomized trials have employed different rATG regimens with various maintenance protocols^{33–35}. Each of these has shown good graft and patient survival rates, with no indication of increased rejection when steroid avoidance is supported by rATG induction (Table 1).

Whether early steroid withdrawal after rATG induction could lead to an increased risk of donor-specific antibody (DSA) development was first studied by Delgado *et al*⁴¹ in low-immunologic risk kidney transplant recipients. In this longitudinal study, performed in 37 patients randomized to early corticosteroid withdrawal at day 7 post-transplant ($n=21$ patients), or to maintenance steroid therapy ($n=16$) – with all patients receiving rATG induction – there was no difference between the two groups in terms of DSA development during five years' follow-up. Interestingly, only one patient developed DSA (in the control group). This is fewer than would be expected, suggesting a protective role for rATG in DSA occurrence. Supportive data were recently published in a study by Brokhof *et al*⁴² undertaken in a population of 114 consecutive moderately sensitized recipients who were divided into two groups based on induction immunosuppression (rATG versus basiliximab). At month 36 post-transplant, there was a lower incidence of *de novo* DSA and antibody-mediated rejection in the rATG group when compared with

basiliximab. However, in this study standard maintenance steroids were given to all patients.

2.2 Alemtuzumab induction

Several randomized trials of steroid-free therapy have employed alemtuzumab induction, at a dose of 30 mg given either once or twice (Table 1). Vathsala and colleagues performed a small, six-month study in which 30 patients were randomized to alemtuzumab with reduced-exposure CsA monotherapy and no oral steroids or to no induction with a conventional CsA-based regimen with steroids and azathioprine³⁶. Graft survival was 85% at month 6 in the alemtuzumab group versus 100% in the control arm, but larger studies of alemtuzumab with reduced-CNI³⁷, delayed CNI³⁷ or tacrolimus monotherapy^{38,39} have not shown any deleterious effect on graft survival when alemtuzumab has been used to support steroid avoidance (Table 1). Consistently, the incidence of BPAR at 12 months post-transplant has been lower with alemtuzumab induction, a reduced-intensity maintenance regimen and a steroid-free protocol versus conventional regimens with^{36,37,40} or without^{38,39} steroids.

The largest trial in this series is the 3C study⁴⁰. A total of 852 patients were randomized to alemtuzumab (30 mg peri-operatively and on the subsequent day) with low-exposure tacrolimus (5–7 ng/mL) and reduced-dose MPA (enteric-coated mycophenolic acid 360 mg b.i.d.), or to a conventional regimen of basiliximab induction, tacrolimus (5–12 ng/mL), standard MPA dosing (540–720 mg b.i.d.) with ongoing oral steroids. During the first six months post-transplant, the risk of BPAR was significantly lower in the alemtuzumab group versus controls (Figure 2). The difference arose during the early weeks after transplantation and was accounted for by a reduced rate of T-cell mediated rejection (hazard ratio [HR] 0.37; 95% confidence interval [CI] 0.23–0.58; $p < 0.0001$);

antibody-mediated rejection was similar in both treatment arms (HR 1.59; 95% CI 0.52–4.86; $p=0.41$)⁴⁰. Graft and patient survival rates at month 6 were similar between groups. Leukopenia was significantly more frequent under alemtuzumab, as would be expected, but there was no between-group difference in opportunistic infections or serious infections. Longer-term follow-up from this trial will be of interest, since at month 6 patients were randomized to remain on tacrolimus or switch to sirolimus. Reconstitution of the lymphocyte population after recovery from alemtuzumab-induced depletion may on one hand have profound effects on the risk of graft rejection, or on the other hand may give rise to more tolerogenic lymphocyte subsets. One recent retrospective study of 200 consecutive non-sensitized kidney transplant patients treated with rapid steroid taper reported that as well as higher rates of acute rejection, three-year graft survival was lower under alemtuzumab induction versus rATG⁴³.

No randomized trial of alemtuzumab with steroid avoidance after kidney transplantation has shown reduced patient survival when followed for up to two years^{36–40}, an important point in view of the severe lymphocyte depletion associated with alemtuzumab and the potential risk for infectious deaths or malignancy.

2. 3 Comparative studies between induction agents within steroid-free regimens

Two registry analyses have specifically assessed outcomes according to type of induction in kidney transplant patients discharged on a steroid-free regimen^{25,44}. Sureshkumar and colleagues analyzed Organ Transplantation and Procurement Network (OPTN) data from 9,172 patients who received a deceased-donor kidney transplant during 2000–2008, with a median follow-up of 26.8 months²⁵. The risk of graft failure after adjustment for a range of potentially confounding variables was found to be significantly higher with alemtuzumab or IL-2R antagonist induction compared to rATG

(Figure 3). Further analyses showed that higher graft survival for rATG versus alemtuzumab was maintained in at-risk populations (sensitized patients [PRA >20%], expanded criteria donor recipients and cold ischemia time >24 hours)²³ but significance was lost in these subpopulations for the comparison between rATG and IL-2R antagonists. Data on rejection were not reported, so it is unclear whether differences in graft failure were related to a lower propensity to rejection under rATG or other causes of graft loss. In a more recent cohort (2000 to 2012) of patients registered with OPTN, Tanriover *et al* analyzed lower-risk living-donor recipients of a first transplant who were discharged on tacrolimus and MMF, with or without steroid therapy⁴⁴. Propensity scoring was used to address the risk of selection bias. Within the subpopulation that was discharged steroid-free (n=10,157), acute rejection at one year post-transplant was significantly lower with either rATG (odds ratio 0.73; 95% CI 0.59–0.90) or alemtuzumab (0.53; 0.42–0.67) versus IL-2R antagonist induction. The one-year risk of graft failure was higher with alemtuzumab versus IL-2R antagonist induction (odds ratio 1.27; 95% CI 1.03–1.56) but similar for rATG versus IL-2RA antagonists (1.19; 0.97–1.45).

Randomized trials comparing steroid avoidance with different induction regimens are relatively rare (Table 2). In a double-blind, placebo-controlled trial of steroid cessation at seven days versus ongoing steroids, both with tacrolimus and MMF, the 191 patients in the steroid-withdrawal group received either rATG (n=125) or an IL-2R antagonist induction (n=66)⁴⁶. In this subpopulation, the five-year incidence of BPAR was 14.4% versus 24.2%, respectively (p=0.09). Results of the ongoing SAILOR study, comparing rATG with steroid avoidance versus IL-2R antagonist induction with standard oral steroids in patients receiving low-dose tacrolimus and concentration-controlled MMF⁵⁰, will help to clarify the relative effectiveness of each class of agent in preventing rejection in the absence of steroids.

In a large trial of kidney transplant patients stratified as either high or low immunological risk, Hanaway and colleagues randomized a 139 high-risk cohort to alemtuzumab or rATG, and 335 low-risk patients to alemtuzumab or basiliximab, all with tacrolimus and MMF; steroids were discontinued by day 5⁴⁶. In the high-risk group, there was no difference in the rate of BPAR between alemtuzumab and rATG at year 3 (Table 2). For low-risk patients, however, alemtuzumab induction was associated with a reduced rate of BPAR versus basiliximab (10% versus 22%, $p<0.001$). A further comparison of alemtuzumab versus rATG will be provided by the BEST study, an ongoing randomized, open-label trial in which patients receive belatacept-based immunosuppression with MPA and early steroid withdrawal, using induction with alemtuzumab in one group and rATG in a second group, or tacrolimus, MPA, early steroid withdrawal and rATG induction (NCT 01729494).

Ciancio *et al* undertook a randomized, single-center study of combined induction protocols in 200 first kidney transplant patients, whereby rATG was combined with either daclizumab or with a single dose of alemtuzumab⁴⁷ (Table 2). All patients were given oral steroids to day 7, with maintenance therapy comprising tacrolimus and MPA. As might be expected with this relatively intensive regimen, rates of BPAR were low in both groups (10% and 9%), although graft survival was numerically higher in the rATG/daclizumab arm (91% versus 83%, n.s.). Early leukopenia was more frequent than with rATG/alemtuzumab induction, despite reduced MPA dosing, than with rATG/daclizumab (12% versus 31%, $p=0.002$)⁴⁷. Other comparative studies of rATG versus alemtuzumab or an IL-2R antagonist using steroid-avoidance regimens have usually been relatively small (<40 patients), with different maintenance protocols and steroid use between treatment arms, limiting interpretation^{48,49} (Table 2). One notable point was a high rate of BPAR (21.4% at month 12) in a small series of kidney-pancreas

patients randomized to alemtuzumab with tacrolimus monotherapy and no oral steroids⁴⁸, but confirmatory data are lacking.

Three randomized trials of alemtuzumab with steroid avoidance have used an IL-2R antagonist in the control arm, as discussed above, but since the maintenance regimen differed between groups the effect of the induction regimen cannot be assessed^{38–40}.

3. Lymphocyte-depleting induction and steroid withdrawal

So far, head-to-head comparisons of steroid withdrawal with or without lymphocyte-depleting induction therapy have not been undertaken. Typically, studies of steroid withdrawal either before or after the first year post-transplant have not included induction therapy^{4,9,10}.

One large study of late (month 3) steroid withdrawal allowed lymphocyte-depleting induction according to local practice. A third of patients (34% and 33% in the steroid-withdrawal and control groups, respectively) received induction, but this included both rATG and monomurab (OKT3)⁵¹. In this subgroup of 169 patients, the 12-month incidence of BPAR was 14% without steroids compared to 17% in the steroids group i.e. steroid withdrawal was successfully achieved. In contrast, for the 331 patients without any induction therapy, BPAR was higher in the steroid-withdrawal patients (29% versus 15% in controls). Although only a subanalysis, these data suggest an advantage for lymphocyte depleting induction when undertaking steroid withdrawal after kidney transplantation.

In the SPIESSER study, 150 moderate-risk or low-risk kidney transplant patients underwent steroid withdrawal at the end of month 5 post-transplant⁴⁹. All patients received rATG induction⁵². The intervention group was randomized to sirolimus and

MMF in a CNI-free regimen, while the control group received CsA and MMF. In both arms, the 12-month incidence of BPAR was low (14% with sirolimus/MMF, 9% with CsA/MMF) and more than 80% of patients remained steroid-free at month 12. Steroid withdrawal around month 6 thus appears feasible under rATG induction with or without CNI therapy, when high-risk patients are excluded.

4. High-immunological risk patients

Steroid-free immunosuppression is less frequently attempted in high-risk patients, and data are limited (Table 3). Two retrospective single-center studies in African-American populations have assessed outcomes following rATG induction with i.v. steroids to day 4, both with a maintenance regimen of tacrolimus combined with either sirolimus or MMF^{43,53}. The one-year rates of BPAR in both series were acceptable for this high-risk group (13–14%), and graft and patient survival was excellent, but firm conclusions cannot be drawn in the absence of prospective trials. One small randomized trial (n=21) selectively recruited high-immunological risk patients (panel reactive antibodies [PRA] >20% or repeat transplantation)⁵⁵. The treatment regimens comprised alemtuzumab (a single dose of 30 mg) with tacrolimus and no steroids, or rATG (total dose 6 mg/kg) with tacrolimus, MMF, and steroids to day 5. In this small series, the rate of BPAR at a median of 12.4 months was 18.2% with alemtuzumab and 37.5% with rATG, while graft survival rates were 85.7% and 87.5%, respectively⁵⁵. These relatively high rates of rejection suggest that steroid avoidance may not be a favorable option in high-risk individuals unless there is a specific clinical imperative. None of these studies employed Luminex[®] technology to define the immunological risk pre-transplant, however, which makes any conclusion uncertain.

5. Steroid minimization and risk of recurrence of glomerular diseases

The advantages of steroid avoidance also have to be balanced against the risk of recurrence of certain glomerulopathies. In particular, several retrospective studies have shown that recurrence of IgA nephropathy is reduced in the presence of long-term steroid therapy. Among them, Clayton *et al*⁵⁸ analyzed data from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) from 1,521 adult recipients of a first kidney transplant in whom kidney failure was due to biopsy-proven IgA nephropathy. After adjustment for various confounding variables, steroid use was strongly associated with a reduced risk of IgA nephropathy recurrence (HR 0.50, 95% CI 0.30–0.84). Only 9% of patients in the study population received depleting induction therapy. Kukla *et al* observed that steroid avoidance may be associated with a higher rate of recurrent glomerulopathy but found no apparent increase in the risk of graft loss in patients treated with rATG induction coupled with maintenance therapy comprising tacrolimus and an antimetabolite⁵⁹. Von Visger and colleagues⁶⁰ recently showed similar results in a cohort of 124 patients, in which 91% of patients in the steroid-free group received lymphocyte-depleting induction. Although the mechanisms involved have not been elucidated, steroid avoidance would not appear advisable in kidney transplant patients in whom kidney failure was caused by IgA nephropathy.

In other types of glomerular diseases with risk of recurrence, such as focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis or lupus nephritis, for which steroids are used as part of the treatment strategy in native kidneys, some centers tend to maintain steroids in the immunosuppressive protocol after transplantation even in the absence of relevant studies.

6. Steroid minimization in pediatric patients

Steroid-sparing strategies are of particular interest in children. Randomized trials of steroid avoidance in pediatric populations under lymphocyte-depleting induction have not, however, been carried out to date. In a single-center prospective study, Chavers *et al* used rATG induction at a relatively high dose (1.5 mg/kg for between five and seven doses) with i.v. steroids to day 5, with CsA and MMF as maintenance therapy³ (Table 3). The rate of BPAR (19% at two years) was acceptable and, importantly, children given the rATG/steroid-free regimen showed significantly improved growth compared to matched controls given oral steroid therapy (mean standard height deviation score -0.9 versus -1.9 in controls; $p=0.003$). Other steroid-related effects (body mass index, lipid profile, blood pressure) were unaffected although leukopenia was reduced ($p=0.02$) and there were fewer Epstein-Barr infections in the steroid-free arm ($p=0.04$)³. Li *et al*, in a single-center retrospective study, achieved a 0% rate of BPAR at a mean of 13 months post-transplant when a relatively high dose of rATG was employed (total dose 9 mg/kg) with no oral steroids, tacrolimus and MMF, but growth data were not reported and there was no comparison versus a steroid-treated cohort. Lastly, a retrospective single-center study by Wittenhagen *et al* has described a low rate of BPAR (9% at one year) in children given lymphocyte-depleting induction (primarily rATG) with different maintenance regimens⁵⁷. Use of depleting induction in a steroid-avoidance regimen using standard maintenance therapy seems adequate to prevent rejection in children following kidney transplantation, and merits a more rigorous examination.

7. Steroid- and CNI-avoidance regimens

A small number of trials have investigated novel immunosuppressive regimens that avoid both steroids and CNI therapy^{61–63}. Ferguson and colleagues randomized 89 kidney transplant recipients at low or moderate immunological risk to one of three groups: the costimulation blocker belatacept with MMF, belatacept with sirolimus, or

tacrolimus with MMF⁶². All patients received rATG induction (total dose 6 mg/kg) with i.v. steroids to day 4 post-transplant and no oral steroids. At one year, rates of BPAR were acceptable with belatacept and MMF (14%), but lower and similar in the belatacept/sirolimus group (4%) and the control arm (3%). More patients in the conventional tacrolimus/MMF group remained steroid-free at month 12, however (93% versus 73% or 77% in the belatacept group). So while promising, a CNI-free strategy may not be optimal for achieving steroid-free immunosuppression even with lymphocyte-depleting induction. Other small trials have also pointed to low or acceptable rates of BPAR when alemtuzumab induction is used to support CNI-free and steroid-free therapy^{61,63}, one of which achieved highly minimized immunosuppression by giving bone marrow infusions⁶³, but such regimens are not currently used in routine practice.

8. Discussion

The literature contains few direct comparisons of steroid minimization regimens versus conventional steroid treatment in kidney transplant patients receiving lymphocyte-depleting induction. Studies are typically relatively small, with limited follow-up periods, and to date, the occurrence of *de novo* antibodies and antibody-mediated rejection is undocumented. Nevertheless, the available data show that the risk of acute rejection is low when rATG induction is given to support steroid-free regimens after kidney transplantation, at least for the first one to two years post-transplant. In the US, it is common practice to use rATG and stop steroids by day 7, and this appears to be a reasonable approach that does not increase the risk of rejection. In contrast, rejection may be more likely under IL-2R antagonist induction using a steroid-avoidance regimen. Induction with alemtuzumab appears effective in supporting steroid-free immunosuppression, although it is not licensed for use in solid organ transplant recipients. For patients at high immunological risk, the limited data available suggest that

steroid minimization may not be advisable even with depleting induction therapy. The availability of single-antigen bead technology, permitting more precise measurement of anti-HLA antibodies, may enable more accurate identification of high-risk individuals and feasibly, expand the pool of patients considered candidates for steroid minimization.

In children, non-randomized studies indicate that depleting induction with standard maintenance therapy effectively prevents acute rejection with steroid avoidance, an encouraging finding given the growth inhibition associated with chronic steroid administration. More ambitious regimens have been attempted which include both steroid avoidance and CNI avoidance, of which depleting induction with maintenance therapy comprising belatacept and sirolimus appears the most promising, but currently can be regarded as an experimental approach.

There is some suggestion that steroid-associated side effects such as dyslipidemia and weight gain are lower with steroid-free immunosuppression, but this has not been shown to translate to an improvement in hard clinical endpoints. Given the lack of strong evidence in this field, no strong conclusions can be made.

Early steroid therapy with subsequent withdrawal (i.e. later than the first one or two weeks post-transplant) may be possible without additional risk of BPAR in patients who have received rATG induction, but while encouraging the data are too sparse for firm conclusions. Where late steroid withdrawal is attempted (months 3 to 6 post-transplant), it seems preferable to employ tacrolimus-based immunosuppression over CsA. Overall, the effectiveness of steroid avoidance regimens in this setting is better documented than subsequent withdrawal strategies.

In summary, there is a suggestion that steroid avoidance is beneficial for patients after renal transplantation, with the potential to avoid or reduce steroid-related comorbidities. Whilst the limited literature seems to indicate that depleting induction therapy could be the treatment of choice for steroid minimization and avoidance in kidney transplantation, the results of prospective randomized, controlled studies are eagerly awaited⁵⁰.

Abbreviations

ANZDATA	Australia and New Zealand Dialysis and Transplant Registry
BPAR	biopsy-proven acute rejection
CI	confidence interval
CNI	calcineurin inhibitor
CsA	cyclosporine
DSA	donor-specific antibody
HR	hazard ratio
IL-2R	interleukin 2 receptor
KDIGO	The Kidney Disease: Improving Global Outcomes
MMF	mycophenolate mofetil
NODAT	new-onset diabetes mellitus
OPTN	Organ Procurement and Transplantation Network
PRA	panel reactive antibodies
rATG	rabbit antithymocyte globulin

Acknowledgements

Funding

The authors attended a meeting at which the data for inclusion in the paper were discussed and presentations made by the authors. The meeting was coordinated by Sanofi but the authors received no remuneration or funding for travel expenses.

Julio Pascual and Marta Crespo are supported by grants FIS PI13/00598 and Redinren RD12/0021/0024

Conflicts of interest

Maarten Naesens has received travel support, research grant or consultancy fees from Sanofi, Novartis, Astellas and Roche.

Stefan Berger has received travel support from Astellas and consultancy fees from Sanofi, Novartis and Astellas.

Luigi Biancone has received travel support, research grant or consultancy fees from Sanofi, Novartis, and Astellas.

Marta Crespo has received public funding for research from the Spanish Ministry of Health and travel support, research grant, consultancy fees or speaker's honoraria from Novartis, Astellas, Sanofi and Abbvie.

Arjang Djamali is a consultant to Sanofi and has received grants from BMS and Takeda.

Alexandre Hertig has received consultancy fees from Sanofi, Bristol-Myers-Squibb, travel grants from Novartis and CSL Behring, and research grant from Astellas and CSL Behring.

Robert Öllinger has no conflicts of interest to declare.

José Portolés has received travel support, research grant or consultancy fees from

Sanofi, Novartis, and Astellas

Andreas Zuckermann has received research grants from Astellas, Roche, Novartis and Sanofi, is a member of the speakers' bureau for Novartis and Sanofi, and is a member of advisory boards for Sanofi and Sandoz.

Julio Pascual has received travel support, research grant or consultancy fees from Sanofi, Novartis and Astellas.

Author contributions

All authors actively contributed to the content of the manuscript during discussions, critically reviewed draft material, and approved the final manuscript for submission.

References

1. Citterio F. Steroid side effects and their impact on transplantation outcome. *Transplantation*, 72 (2001), pp. S75–80.
2. Rizzari MD, Suszynski TM, Gillingham KJ, Dunn TB, Ibrahim HN, Payne WD, et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. *Clin J Am Soc Nephrol*, 7 (2012), pp. 494–503.
3. Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. *Transplantation*, 88 (2009), pp. 237–241.
4. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrol Dial Transplant*, 27 (2012), pp. 825–832.
5. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC; TRIMS Study Investigators. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. *Clin Transplant*, 24 (2010), pp. 73–83.
6. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. *Am J Kidney Dis*, 33 (1999), pp. 829–839.
7. Schweizer RT, Rovelli M, Palmerl D, Vossler e, Hull D, Bartus S. Noncompliance in organ transplant recipients. *Transplantation*, 49 (1990), pp. 374–377.
8. Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. Renal transplant recipient attitudes toward steroid use and steroid withdrawal. *Clin Transplant*, 17 (2003), pp. 135–139.
9. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients. *Cochrane Database Syst Rev*, 1 (2009), pp. CD005632.
10. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. *Transplantation*, 90 (2010), pp. 343–349.
11. Ponticelli C, Tarantino A, Segoloni GP, Cambi V, Rizzo G, Altieri P, et al. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTre). *J Am Soc Nephrol*, 8 (1997), pp. 638–646.
12. Vítko S, Klinger M, Salmela K, Włodarczyk Z, Tydèn G, Senatorski G, et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. *Transplantation*, 80 (2005), pp. 1734–1741.
13. Tarantino A, Aroldi A, Stucchi L, Montagnino G, Mascaretti L, Vegeto A, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. *Transplantation*, 52 (1991), pp. 53–57.
14. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J; FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. *Am J Transplant*, 8 (2008), pp. 307–316.
15. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, et al; Carmen Study Group. Corticosteroid-free immunosuppression with tacrolimus,

- mycophenolate mofetil, and daclizumab induction in renal transplantation. *Transplantation*, 79 (2005), pp. 807–814.
16. Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy El-M, Aghoneim M. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. *Exp Clin Transplant*, 5 (2007), pp. 673–679.
 17. Kumar MS, Xiao SG, Fyfe B, Sierka D, Heifets M, Moritz MJ, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. *Clin Transplant*, 19 (2005), pp. 61–69.
 18. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. *Am J Transplant*, 3 (2003), pp. 306–311.
 19. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. *Am J Transplant*, 2 (2002), pp. 48–56.
 20. Mourad G, Rostaing L, Legendre c, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. *Transplantation*, 78 (2004), pp. 584–590.
 21. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM. et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. *Transplantation*, 80 (2005), pp. 457–465.
 22. Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. *Nephrol Dial Transplant*, 23 (2008), pp. 2024–2032.
 23. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. *N Eng J Med*, 355 (2006), pp. 1967–1977.
 24. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. *J Am Soc Nephrol*, 20 (2009), pp. 1385–1392.
 25. Sureshkumar KK, Thai NL, Hussain SM, Ko TY, Marcus RJ. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression. *Transplantation*, 93 (2012), pp. 799–805.
 26. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. *J Am Soc Nephrol*, 11 (2000), pp. 1910–1917.
 27. Pascual J, Quereda C, Zamora J, Hernández D; Spanish Group for Evidence-Based Medicine in Renal Transplantation. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. *Transplantation*, 78 (2004), pp. 1548–1556.
 28. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*, 9(Suppl 3) (2009), pp. S1–155.

29. Vanrenterghem Y, Van Hooff JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. *Am J Transplant*, 5 (2005), pp. 87–95.
30. Sola E, Alf  rez MJ, Cabello M, Burgos D, Gonz  lez Molina M. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. *Transplant Proc*, 34 (2002), pp. 1689–1690.
31. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. *Am J Transplant*, 5 (2005), pp. 1529–1536.
32. Laftavi MR, Stephan R, Stefanick B, Kohli R, Dagher F, Applegate M, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. *Surgery*, 137 (2005), pp. 364–371.
33. Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. *Transplantation*, 85 (2008), pp. 1391–1399.
34. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. *Transplantation*, 86 (2008), pp. 67–74.
35. Grafals M, Smith B, Murakami N, Trabucco A, Hamill K, Marangos E, et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. *PLOS One*, 9 (2014), pp. e104408.
36. Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola CB, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. *Transplantation*, 80 (2005), pp. 765–774.
37. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller c, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. *Am J Transplant*, 8 (2008), pp. 1480–1485.
38. Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. *Transplantation*, 92 (2011), pp. 774–780.
39. Welberry Smith MP, Cherukurl A, Newstead CG, Lewington AJ, Ahmad N, Menon K, et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. *Transplantation*, 96 (2013), pp. 1082–1088.
40. 3C Study Collaborative Group, Haynes R, Harden P, Judge P, Blackwell L, Emberson J, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. *Lancet*, 384 (2014), pp. 1684–1690.
41. Delgado JC, Fuller A, Ozawa M, Smith L, Terasaki PI, Shihab FS, et al. No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study. *Transplantation*, 87 (2009), pp. 546–548.
42. Brokhof MM, Sollinger HW, Hager DR, Muth BL, Pirsch JD, Fernandez LA, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-

specific antibodies in moderately sensitized renal transplant recipients. *Transplantation*, 97 (2014), pp. 612–617.

43. Saull HE, Enderby CY, Gonwa TA, Wadei HM. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. *Clin Transplant*, 29 (2015), pp. 573–580.
44. Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU, et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. *Clin J Am Soc Nephrol*, 10 (2015), pp. 1041–1049.
45. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*, 248 (2008), pp. 564–577.
46. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction in renal transplantation. *New Engl J Med*, 364 (2011), pp. 1909–1919.
47. Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. *Transplantation*, 92 (2011), pp. 1348–1357.
48. Bösmüller C, Ollinger R, Sieb M, Weissenbacher A, Schneeberger S, Pratschke J, et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. *Ann Transplant*, 17 (2012), pp. 45–51.
49. Ciancio G, Gaynor JJ, Roth D, Kupin W, Hanson L, Tueros L, et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. *Transplant Proc*, 42 (2010), pp. 3503–3506.
50. Ekberg J, Ekberg H, Jespersen B, Källen R, Skov K, Olausson M, et al. An in-progress, open-label, multi-centre study (SAILOR) evaluating whether a steroid-free immunosuppressive protocol, based on ATG induction and a low tacrolimus dose, reduces the incidence of new onset diabetes after transplantation. *Transplant Res*, 3 (2014), p.12.
51. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. *Transplantation*, 70 (2000), pp. 1352–1359.
52. Büchler M, Caillard S, Barbier S, Thervet E, Touponce O, Mazouz H, et al; SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. *Am J Transplant*, 7 (2007), pp. 2522–2531.
53. Haririan A, Sillix DH, Morawski K, El-Amm JM, Garnick J, Doshi MD, et al. Short-term experience with early steroid withdrawal in African-American renal recipients. *Am J Transplant*, 6 (2006), pp. 2396–2402.
54. Zeng X, El-Amm JM, Doshi MD, Singh A, Morawski K, Cincotta E, et al. Intermediate-term outcomes with early steroid withdrawal in African-American renal transplant recipients undergoing surveillance biopsy. *Surgery*, 142 (2007), pp. 538–544.

55. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. *Transplantation*, 83 (2007), pp.1509–1512.
56. Li L, Chaudhuri A, Chen A, Zhao X, Bezchinsky M, Concepcion W, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. *Transplantation*, 90 (2010), pp.1516–1520.
57. Wittenhagen P, Thiesson HC, Baudier F, Pedersen EB, Neland M. Long-term experience of steroid-free pediatric renal transplantation: effects on graft function, body mass index, and longitudinal growth. *Pediatr Transplant*, 18 (2014), pp. 35–41.
58. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. *Am J Transplant*, 11 (2011), pp. 1645–1649.
59. Kukla A, Chen E, Spong R, Weber M, El-Shahawi Y, Gillingham K, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids. *Transplantation*, 91 (2011), pp. 1386–1391.
60. Von Visger JR, GunaY Y, Andreoni KA, Bhatt UY, Nori US, Pesavento TE, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression. *Clin Transplant*, 28 (2014), pp. 845–854.
61. Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA. Alemtuzumab preconditioning allows steroid-calcineurin-free regimen in live-donor kidney transplant. *Exp Clin Transplant*, 5 (2011), pp. 295–301.
62. Ferguson R, Grinyo J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. *Am J Transplant*, 11 (2011), pp. 66–76.
63. Kirk AK, Guasch A, Xu H, Cheeseman J, Mead SI, Ghali A, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. *Am J Transplant*, 14 (2014), pp. 1142–1151.

Table 1. Randomized trials of rATG or alemtuzumab induction with steroid avoidance in kidney transplantation

Study	Risk status N	Study duration	rATG	Steroids	Maintenance	BP AR (%)	Graft/patient survival (%) ^a
rATG induction							
Kandaswamy 2005 ³¹ Single center	Unselected N=239	2Y	1.25-1.5 mg/kg x 5	i.v. + oral to day 5	CsA, MMF	6	95/98
					High TAC Low SRL	4	94/97
					Low TAC High SRL	5	96/97
Laftavi 2005 ³² Single center	Moderate/low N=60	12M	1 mg/kg x 3-5	i.v.+ oral to day 7	TAC, MMF	13	-
				i.v.+ oral ongoing		11	-
Stevens 2008 ³³ Single center	Moderate/low N=180	6M	6 mg/kg x 1	i.v. only (< 7 days)	TAC/SRL or MMF/SRL	8	100/100
			1.5 mg x 4			12	98.6/96
Ciancio 2008 ³⁴ Single center	Unselected N=150	12M	1 mg/kg x 3 + daclizumab 1 mg/kg x 2	i.v.+ oral (< 7 days)	TAC, MMF	3	97/100
					TAC, EC-MPS	9	96/99
Woodle 2010 ⁵ Multicenter	Living donor Moderate/low N=151	12M	1.25-1.5 mg/kg x 4	i.v.+ oral (< 7 days)	TAC, MMF	13.9	98.1/100
			No rATG	i.v. + oral ≥ 3M		19.4	97.9/100
Grafals 2014 ³⁵ Single center	Low N=45	12M	0.75 mg/kg x 3	i.v.+ oral (< 7 days)	TAC, MMF	10	85/85
			1.24 mg/kg x 3			17	100/100
Alemtuzumab induction							
Vathsala 2005 ³⁶ Multicenter	Moderate/low N=30	6M	ALEM 20 mg x 2	i.v. x 1	Reduced CSA	25	85/95
			None	Standard	CSA, AZA	20	100/100
Margreiter 2008 ³⁷ Multicenter	Moderate/low N=131	12M	ALEM 20 mg x 2	i.v. x 2	Delayed TAC	20	96/98
			None	Standard	TAC, MMF	32	90/98
Chan 2011 ³⁸ Single center	Unselected N=123	24M	ALEM 30 mg x 1	i.v. + oral to day 7	TAC	11.1	97.6/100
			DAC 2 mg/kg x 3		TAC, MMF	17.7	95.1/97.5
Welberry Smith 2013 ³⁹ Single center	Moderate/ low N=116	12M	ALEM 30 mg x 1	i.v. x 1	TAC	10.3	94.9/96.6
			BAS 20 mg x 2		TAC, MMF	24.1 ^b	94.8/96.6

3C Study Group 2014 Multicenter ⁴⁰	Unselected (4% sensitized) N=852	6M	ALEM 30 mg x 2	None	Reduced TAC Reduced MMF	7	96/97
			BAS 20 mg x 2	Oral (ongoing)	TAC, MMF	16 ^c	97/99

ALEM, alemtuzumab; BAS, basiliximab; BPAR, biopsy-proven acute rejection; CsA, cyclosporine; DAC, daclizumab; EC-MPS, enteric-coated mycophenolate sodium; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SRL, sirolimus; TAC, tacrolimus

^a At end of study (see Study duration in column 3) ^b p=0.049 ^c p<0.0001

Table 2. Randomized comparative trials of induction therapy with steroid avoidance in kidney transplantation

Study	Risk status N	Study duration	Induction	Steroids	Maintenance	BPAR (%)	Graft/patient survival (%) ^a
Woodle 2008 ⁴⁵ Multicenter	Low or moderate N=191	5Y	rATG 1.5 mg/kg x 4	i.v./oral to day 7	TAC	14.4	-
			IL-2RA ^b		MMF	24.2	-
Hanaway 2011 ⁴⁶	High N=139	3Y	Alemtuzumab 30 mg x 1	Steroids ≤5 days	TAC MMF	18	99
			rATG 1.5mg/kg x 4			15	91
	Low N=335		Alemtuzumab 30 mg x 1			10 ^c	95
			BAS 20 mg x 2			22 ^c	98
Ciancio 2011 ⁴⁷ Single center	Unselected N=200	Median 38M	rATG 1 mg/kg x 3 + DAC 1 mg/kg x 2	i.v. x 3 ± oral (< day 7)	Reduced TAC EC-MPS	10	91/96 (4 years)
			rATG 1 mg/kg x 1 + ALEM 0.3 mg/kg x 1		Reduced TAC 50% EC-MPS	9	83/92 (4 years)
Bösmüller 2012 ⁴⁸ Single center	Kidney- pancreas N=30	12M	ALEM 30 mg x 1	i.v. x 1	TAC	21.4	92.8/100
			rATG 4 mg/kg x 1 or ATG-F 8 mg/kg x 1	i.v. x 2 + oral to month 3	TAC, MMF	0	87.5/100
Ciancio 2010 ⁴⁹ Single center	Living donor N=38	Median 47M	rATG 1 mg/kg x 7	i.v. x 3 + oral ongoing	TAC MMF	0	100/100
			ALEM 0.3 mg/kg x 2	i.v. x 2 + oral (≤day 7)	TAC 50% MMF	7.7	92.3/92.3
			DAC 1 mg/kg x 5	i.v. x 3 + oral ongoing	TAC MMF	8.3	100/100

* At end of study (see Study duration in column 3)

^b Basiliximab or daclizumab^c p=0.003 ALEM, alemtuzumab; BAS, basiliximab; BP/AR, biopsy-proven acute rejection; EC-MPS, enteric-coated mycophenolate sodium; IL-2RA, interleukin 2 receptor antagonist; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; TAC, tacrolimus

Table 3. rATG or alemtuzumab induction with steroid avoidance in high-risk or pediatric kidney transplant populations

Study	Population N	Study duration	Induction	Steroids	Maintenance	BPAP (%)	Graft/patient survival (%) ^a
High immunological risk							
Haririan 2006 ⁵³ Single center Retrospective Cohort study	African-American N=73	12M	rATG 1.5 mg/kg Mean 4.3 doses	i.v. to day 4	TAC or SRL, MMF	13	100/-
			rATG 1.5 mg/kg Mean 7.1 doses	i.v. + oral ongoing		15	97/-
Zeng 2007 ⁵⁴ Single center Retrospective	African-American N=57	12M	rATG 1.5 mg/kg x 4	i.v. to day 4	TAC or SRL, MMF	14	96/98
Thomas 2008 ⁵⁵ Single center Randomized	High risk ^b N=21	Median 12.4M	Alemtuzumab 30 mg x 1	i.v. x 1	TAC	18.2	85.7/100 (1 year)
			rATG 1.5 mg/kg x 4	i.v. + oral to day 5	TAC, MMF	37.5	87.5/87.5 (1 year)
Children							
Chavers 2009 ³ Single center Prospective Matched controls	Age 7.8-18 N=60	2Y	rATG 1.5 mg/kg x 5-7	i.v. to day 5	CSA, MMF	19	86/95 ^c
			rATG 1.5 mg/kg x 6-15	Oral steroids ongoing	CSA, AZA	31	90/97 ^c
Li 2010 ⁵⁶ Single center Retrospective control group	rATG: High risk DAC: Low-risk Mean ~14Y N=26	Mean 13M	rATG 1.5 mg/kg x 6	i.v. to day 6	TAC, MMF	0	100/-
			DAC to M6	None	TAC, MMF	0	100/-
Wittenhagen 2014 ⁵⁷ Single center Retrospective	Age 1.1-14.9Y N=65	≤10Y	ATG to 1999 then rATG 1.25 mg/kg 5-10 days	None	CSA to 1995, CSA/MMF to 2004, TAC/MMF to 2009	9 (1 year)	71/93 (10 years) ^d

^a At end of study (see Study duration in column 3) unless otherwise stated

^b Panel reactive antibodies >20% or retransplantation

^c Significantly improved growth in steroid-free group (mean standard height deviation score -0.9 vs -1.9 [p=0.003]). Body mass index was similar in both groups

^d Significantly improved growth after transplantation (mean standard height deviation score increased from -1.7 to -1.1 [$p=0.007$]). Body mass index remained stable
AZA, azathioprine; BPAR, biopsy-proven acute rejection; CSA, cyclosporine; DAC, daclizumab; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SRL, sirolimus; TAC, tacrolimus

Figure legends

Figure 1. Freedom from biopsy-proven acute rejection (BPAR), in moderate- or low-risk living donor kidney transplant patients randomized to rabbit antithymocyte globulin (rATG) with intravenous steroids only, or to no steroids with intravenous steroids and oral steroids for ≥ 3 months, both with tacrolimus (TAC) and mycophenolate mofetil (MMF) (Kaplan-Meier estimates). No statistical analysis was provided (observed rates of BPAR: 13.9% for rATG/TAC/MMF versus 19.4% for TAC/MMF/steroids; $p=NS$). Reproduced with permission from⁵.

Figure 2. Incidence of biopsy-proven acute rejection (BPAR) in 852 unselected kidney transplant patients randomized to alemtuzumab induction with low-exposure tacrolimus, low-dose mycophenolic acid and no steroids, or to basiliximab induction with standard tacrolimus, standard mycophenolic acid and standard steroids. HR, hazard ratio; CI, confidence interval. Reproduced with permission from⁴⁰.

Figure 3. Probability of graft survival after adjustment for prespecified donor, recipient and transplant-related variables in deceased-donor kidney transplants performed during 2000–2008 registered with the Organ Procurement and Transplantation Network (OPTN) who were discharged on steroid-free immunosuppression. HR, hazard ratio; CI, confidence interval; rATG, rabbit antithymocyte globulin; IL-2R, interleukin-2 receptor. Reproduced with permission²⁵.